U.S. Peripheral Nerve Injuries Market to Touch USD 824.23 million by 2032
The U.S. peripheral nerve injuries market size accounted for USD 406.29 million in 2022 and is estimated to achieve a market size of USD 824.23 million by 2032 growing at a CAGR of 7.33% from 2023 to 2032.
Key Takeaways:
U.S. Peripheral Nerve Injuries Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 436.07 million |
| Market Size by 2032 | USD 824.23 million |
| Growth Rate From 2023 to 2032 | CAGR of 7.33% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Product/therapies, Surgery, Application, End-use |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Key Companies Profiled | Axogen Corporation; Stryker/Collagen Matrix/Polyganics BV; Integra Lifesciences Corporation; Toyobo Co., Ltd.; Alafair Bioscience; Synovis Micro Companies Alliance, Inc. (Baxter International, Inc.) |
The growth of the market is due to increasing healthcare expenditure in the U.S., an increasing prevalence of peripheral nerve injuries, growing focus on research and development, and a growing patient preference for minimally invasive procedures.
Technological advancements are revolutionizing the field of peripheral nerve injury treatment in the U.S. New and innovative treatment options such as nerve grafts, nerve conduits, and neurostimulation devices are providing improved outcomes and helping patients recover faster. Additionally, the use of minimally invasive surgical techniques, such as end-to-end nerve sutures and nerve decompression procedures, is gaining popularity among patients due to their benefits of faster recovery times. These advancements in medical technology are driving the growth of the market by providing more effective and less invasive treatment options.
Investments from key market players and collaborations between academia, industry, and healthcare institutions are driving R&D efforts, leading to the discovery of new treatment modalities. For instance, in June 2022, Vascudyne, Inc., a leading biotechnology company in regenerative medicine, was awarded a grant from Regenerative Medicine Minnesota for a research study titled "Production of a Peripheral Nerve Wrap Using Tissue Tubes from Regenerative Engineering." The study will be funded with USD 100,000 for one year, starting in June 2022, and will utilize Vascudyne's TRUE Tissue technology.
The COVID-19 pandemic has boosted the demand for minimally invasive procedures as it offer benefits such as shorter recovery times, potentially lower costs, better treatment options, and integration with telemedicine technologies. These factors may impact the market for U.S. peripheral nerve injuries positively.
Products/Therapies Insights
Based on products/therapies, nerve grafting captured the largest market share of 65.99% in 2022. Nerve grafting is required or performed when a patient experiences a complete loss of sensation or muscle function resulting in nerve injury. It is a surgical technique that involves the replacement or bridging of an injured nerve portion with another unrelated nerve. The segment is anticipated to grow as a result of numerous strategic activities, including product launches, partnerships, and collaborations. For instance, in May 2022, Axogen, Inc. released the findings of a clinical study comparing RECON from Axogen with conduits to Avance Nerve Graft. Phase 3 pivotal research met the target for the recovery of sensory function. In the second half of 2023, the corporation may use this information to submit a Biologics License Application (BLA).
The biomaterial segment is anticipated to grow at the fastest CAGR during the forecast period. Peripheral nerve injuries are a global challenge that results in long-term disability and reduced quality of life for patients. Such injuries are common and often require surgery due to the complexity & extent of the injury. Autografts are the current gold standard in clinical intervention, despite drawbacks such as donor site morbidity and lack of donor neural tissue. Therefore, the use of nerve conduits (NGCs) is an attractive alternative for the treatment of peripheral nerve damage. Biomaterials are designed to provide a protective layer over injured peripheral nerves and provide a semipermeable, resorbable sheath to facilitate nerve repair.
Surgery Insights
Based on surgery, direct nerve repair captured the largest market share of 42.69% in 2022. Direct nerve repair (also known as end-to-end neurorrhaphy) is considered the gold standard of surgical treatment for severe cases. These injuries lead to a loss of ability to communicate due to malfunction of motor & sensory nerves between the peripheral organs and the central nervous system (CNS), resulting in impairment. Direct nerve repair and autologous nerve grafts are still the gold-standard treatment options. Additionally, nerve conduits are very successful to provide an ideal peripheral support for neuronal recovery but are still insufficient. Moreover, an increasing number of traumatic accidents may lead to peripheral nerve injuries that may require surgical intervention, thereby impelling the segment growth.
However, the stem cell therapy segment is expected to expand at the fastest CAGR during the forecast period. Increase in government initiatives and approvals to conduct clinical trials is anticipated to fuel the market. There are approximately 2,754 (2021) in the U.S. that provide stem cell therapy, with the number likely to expand. A stem cell injection can cost around USD 8,000 to 30,000. Although many of these do not follow FDA regulations, they have been proven effective in the treatment of multiple conditions. The FDA has recommended these cells be controlled similar to drugs due to safety concerns raised by them. As a result, clinics may expect more stringent approval procedures in the future. These factors would further drive the segment growth.
Application Insights
Based on the application, the upper extremities segment captured the largest market share of 81.29% in 2022. Treatment of peripheral nerve injuries in the upper extremity involves nerve grafting, nerve transfer, or surgical repair. Increasing number of upper extremities is expected to impel the segment growth over the forecast period. Furthermore, the increasing incidence of accidental falls and medical conditions, such as Guillain-Barre syndrome, diabetes, and carpal tunnel syndrome, is expected to drive the segment. For instance, as per the CDC, every year, 3 million elderly people are treated in fall injury departments.
However, the lower extremities segment is expected to grow at the fastest CAGR during the forecast period. Increasing number of fractures and ligament injuries can lead to lower extremity injuries. Various nerve grafts, such as allografts & synthetic nerve grafts, can be used in the treatment of lower extremities. Several product launches and clinical trials, such as the Avance nerve graft by Axogen, Inc., are expected to boost the segment.
End-use Insights
Based on end use, the hospitals segment captured the largest market share of 60.09% in 2022. Hospitals have trained medical staff who can assess each patient. Increasing number of hospitals and surgical cases in hospitals are expected to boost the segment. In addition, hospitals may provide patients with education and advice on surgical care which may help promote healing. Thus, with the increasing number of hospitals, and hospitalization cases, the segment is expected to have significant growth over the forecast period.
However, the ambulatory surgical centers segment is expected to grow at the fastest rate during the forecast period. Ambulatory surgical centers have some advantages, such as shortened hospital stays. Moreover, various government initiatives are being undertaken to spread awareness about the benefits of surgical treatments in these centers, such as early mobilization of patients, low risk of hospital-acquired infections, and rapid recovery, thus, driving the segment growth.
Some of the prominent players in the U.S. Peripheral Nerve Injuries Market include:
Segments Covered in the Report
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the U.S. Peripheral Nerve Injuries market.
By Products/Therapies
By Surgery
By Application
By End-use
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Products/Therapies
1.1.2. Surgery
1.1.3. Application
1.1.4. End-use
1.1.5. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database.
1.3.2.Nova one advisor’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Approach 1: Commodity flow approach
1.6.3. Volume price analysis (Model 2)
1.6.4. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product/Therapies Outlook
2.2.2. Surgery Outlook
2.2.3. Application Outlook
2.2.4. End-use Outlook
2.3. Competitive Insights
Chapter 3. U.S. Peripheral Nerve Injuries Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Industry Value Chain Analysis
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.1.1. Increasing government funding and reimbursement
3.3.1.2. Technological advancement
3.3.1.3. Rising medical tourism
3.3.2. Market restraint analysis
3.3.2.1. Lack of awareness among patients for treatment of peripheral nerve injuries
3.3.2.2. High cost of treatment
3.3.3. Market opportunity analysis
3.3.3.1. Increasing demand for 3D bioprinting applications
3.4. U.S. Peripheral Nerve Injuries Market Analysis Tools
3.4.1. Industry Analysis – Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
3.4.3. Major Deals & Strategic Alliances Analysis
3.4.4. Market Entry Strategies
Chapter 4. U.S. Peripheral Nerve Injuries Market: Product/Therapies Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Nerve Grafting
4.1.2. Accessories
4.2. Product/Therapies Market Share, 2023 & 2032
4.3. Segment Dashboard
4.4. U.S. Peripheral Nerve Injuries Market by Product/Therapies Outlook
4.5. Market Application & Forecasts and Trend Analyses, 2020 to 2032 for the following
4.5.1. Nerve Grafting
4.5.1.1. Market estimates and forecast 2020 - 2032
4.5.1.2. Autograft
4.5.1.2.1. Market estimates and forecast 2020 - 2032
4.5.1.3. Allograft
4.5.1.3.1. Market estimates and forecast 2020 - 2032
4.5.1.4. Stem Cell Therapy
4.5.1.4.1. Market estimates and forecast 2020 - 2032
4.5.2. Biomaterial
4.5.2.1. Market estimates and forecast, 2020 - 2032
4.5.2.2. Nerve Conduit
4.5.2.2.1. Market estimates and forecast 2020 - 2032
4.5.2.3. Nerve Protector
4.5.2.3.1. Market estimates and forecast 2020 - 2032
4.5.2.4. Nerve Connector
4.5.2.4.1. Market estimates and forecast 2020 - 2032
4.5.2.5. Nerve Wraps
4.5.2.5.1. Market estimates and forecast 2020 - 2032
Chapter 5. U.S. Peripheral Nerve Injuries: Surgery Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Direct nerve repair
5.1.2. Nerve Grafting
5.1.3. Stem Cell Therapy
5.1.4. Carpal Tunnel Release
5.1.5. Internal Neurolysis
5.1.6. Neurorrhaphy
5.2. Surgery Market Share, 2023 & 2032
5.3. Segment Dashboard
5.4. U.S. Peripheral Nerve Injuries Market by Surgery Outlook
5.5. Market Application & Forecasts and Trend Analyses, 2020 to 2032 for the following
5.5.1. Direct Nerve Repair
5.5.1.1. Market estimates and forecast, 2020 - 2032
5.5.1.2. Nerve Grafting
5.5.1.2.1. Market estimates and forecast, 2020 - 2032
5.5.1.3. Stem Cell Therapy
5.5.1.3.1. Market estimates and forecast, 2020 - 2032
5.5.1.4. Carpal Tunnel Release
5.5.1.4.1. Market estimates and forecast, 2020 - 2032
5.5.1.5. Internal Neurolysis
5.5.1.5.1. Market estimates and forecast, 2020 - 2032
5.5.1.6. Neurorrhaphy
5.5.1.6.1. Market estimates and forecast, 2020 - 2032
Chapter 6. U.S. Peripheral Nerve Injuries: Application Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Upper Extremities
6.1.2. Lower Extremities
6.2. Surgery Market Share, 2023 & 2032
6.3. Segment Dashboard
6.4. U.S. Peripheral Nerve Injuries Market by Application Outlook
6.5. Market Application & Forecasts and Trend Analyses, 2020 to 2032 for the following
6.5.1. Upper Extremities
6.5.1.1. Market estimates and forecast, 2020 - 2032
6.5.1.2. Lower Extremities
6.5.1.2.1. Market estimates and forecast, 2020 - 2032
Chapter 7. U.S. Peripheral Nerve Injuries: End-use Estimates & Trend Analysis
7.1. Definitions and Scope
7.1.1. Hospitals
7.1.2. Clinics
7.1.3. Ambulatory surgical centers
7.1.4. Others
7.2. End-use Market Share, 2023 & 2032
7.3. Segment Dashboard
7.4. U.S. Peripheral Nerve Injuries Market by End-use Outlook
7.5. Market Application & Forecasts and Trend Analyses, 2020 to 2032 for the following
7.5.1. Hospitals
7.5.1.1. Market estimates and forecast, 2020 - 2032
7.5.2. Clinics
7.5.2.1. Market estimates and forecast, 2020 - 2032
7.5.3. Ambulatory surgical centers
7.5.3.1. Market estimates and forecast, 2020 - 2032
7.5.4. Others
7.5.4.1. Market estimates and forecast, 2020 - 2032
Chapter 8. U.S. Peripheral Nerve Injuries Market: Country Estimates & Trend Analysis
8.1. Country market share analysis, 2023 & 2032
8.2. Country Market Dashboard
8.3. Market Application, & Forecasts and Trend Analysis, 2020 to 2032:
8.3.1. U.S.
8.3.1.1. Key country dynamics
8.3.1.2. Competitive Scenario
8.3.1.3. Regulatory framework
8.3.1.4. Reimbursement scenario
8.3.1.5. U.S. market estimates and forecasts, 2020 - 2032
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.2.1. Innovators
9.2.2. Market Leaders
9.2.3. Emerging Players
9.3. Vendor Landscape
9.3.1. Axogen Corporation
9.3.1.1. Company overview
9.3.1.2. Financial performance
9.3.1.3. Product benchmarking
9.3.1.4. Strategic initiatives
9.3.2. Stryker/Collagen Matrix/Polyganics BV
9.3.2.1. Company overview
9.3.2.2. Financial performance
9.3.2.3. Product benchmarking
9.3.2.4. Strategic initiatives
9.3.3. Integra Lifesciences Corporation
9.3.3.1. Company overview
9.3.3.2. Financial performance
9.3.3.3. Product benchmarking
9.3.3.4. Strategic initiatives
9.3.4. Toyobo Co., Ltd.
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Alafair Bioscience
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Synovis Micro Companies Alliance, Inc. (Baxter International, Inc.)
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.7. Strategic initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers